Navigation Links
Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
Date:10/25/2011

AMSTERDAM, October 25, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today provided an update on operations and disclosed the outcome of a strategic review of its gene therapy product pipeline conducted by management and AMT's Board of Directors that enables the company to remain at the forefront of gene therapy development. The CHMP's recent opinion, while not approving Glybera®, did not identify any safety risks with AMT's adeno-associated virus vector technology. This will allow AMT to leverage its expertise and strength in building other portfolio products. The selection of specific pipeline products is aimed at securing partnering agreements that will provide solid financial foundations to take the company forward. Existing shareholders continue to see promise in the technology and are in discussions with AMT to provide additional equity.

Pipeline

AMT will focus development efforts and financial resources on three gene therapy programs: hemophilia B, GDNF and acute intermittent porphyria. The Company will continue participating in the SanfilippoB program, which is fully funded by a consortium led by Institut Pasteur. Further investment in and development of Glybera and the Duchenne's muscular dystrophy program has been suspended.

The company intends to support the development of its product pipeline through partnering agreements. Negotiations are being conducted for two programs.

Glybera®

Following the negative opinion provided by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for Glybera (alipogene tiparvovec) as a treatment of lipoprotein lipase deficiency (LPLD), AMT has suspended the program. Consequently, AMT does not expect that Glybera will reach European patients. AMT decided that further investment in Glybera, in light of requirements necessary for approval and with the current financi
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
4. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
5. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
6. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
7. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
8. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
9. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- Cambrex Corporation (NYSE: CBM ) reports results ... Highlights , Second quarter sales increased 59% ... last year. , Second quarter EBITDA increased 86% to ... last year (see table at the end of this release). ... impact of foreign currency, to between 13% and 16% over ...
(Date:7/31/2014)... August 01, 2014 “2014 ... Polyurethane Resin Industry” is a professional and ... The report introduces Polyurethane Resin basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
(Date:7/31/2014)... is famous for a number of breakthroughs, which altered ... published a paper, which laid the foundation of computer ... algorithm. He next played a pivotal role in the ... German military codes, enabling the Allies to defeat the ... 1940,s he turned his attention to artificial intelligence and ...
(Date:7/31/2014)... COLORADO SPRINGS, Colo. , July 31, 2014 ... Seed Grant awardee today with $25,000 to fund ... the Foundation,s inception in 2011, the gift was ... 11 th Annual Meeting in ... physicians who specialize in neurointerventional approaches to neurovascular ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3
... long-awaited speaking faculty for the September Pharma ChemOutsourcing ... conference website reports Mark Alexay, President of Apaporis ... comprised of 100 speakers from pharmaceutical companies and ... the pipeline. The speaker list may be viewed ...
... Christine Lawless, MD, has accepted the position as ... continuing medical education (CME), beginning March 2, 2009. Recognized ... medicine cardiology, Dr. Lawless recently completed her clinical tenure ... where she was Associate Professor of Internal Medicine and ...
... Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, Inc. today ... trial in patients with Sleep Maintenance Insomnia (SMI). ... wave sleep and decreased the duration of wake after ... prespecified primary and key secondary endpoints of the trial. ...
Cached Biology Technology:Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ 2Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7
(Date:7/31/2014)... found to be a key gene responsible for hearing in ... cells of the inner ear that contracts and expands rapidly ... phonograph horn, amplify sound waves to make hearing more sensitivity. ... advanced online edition of Molecular Biology and Evolution , ... independently evolved to play a critical role in the ultrasonic ...
(Date:7/31/2014)... By tracing nearly 3,000 genes to the earliest ... Florida scientists have created an extensive "Tree of ... next-generation DNA sequencing. , Among the study,s ... to small moths than to large ones, which ... The study also found that some insects once ...
(Date:7/31/2014)... studied 100 twin pairs have identified a gene mutation that ... six hours of sleep per night. The genetic variant ... sleep deprivation. , Results show that a participant with p.Tyr362His ... average nightly sleep duration of only five hours, which was ... slept for about six hours and five minutes per night. ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Study of twins discovers gene mutation linked to short sleep duration 2
... A new technique for transplanting the ovaries of women ... cancer treatment was outlined to the 25th annual conference ... today (Monday 29 June). Dr. Pascal Piver, ... Limoges, France, described a new, two-step method of ovarian ...
... Shingu City, Japan--Deepsea Drilling Vessel CHIKYU has resumed IODP ... the Kii Peninsula of Japan. The scientific drilling expedition,s ... meters. Following sea floor surveys, the crew began fitting ... an upper section of the first borehole to be ...
... June 2009 Elsevier, the leading publisher of scientific, ... the highlights of its journal impact factor performance in ... factors (IF) increase from 2007 to 2008. According to ... journals took the #1 position in 51 categories (of ...
Cached Biology News:Ovarian transplantation: First baby is born after a new technique 2First riser-drilling research operations undertaken 2Elsevier announces 2008 journal impact factor highlights 2Elsevier announces 2008 journal impact factor highlights 3
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
... The APO-BRDU Kit is a 2-color staining ... cellular DNA to detect apoptotic cells by ... and reagents required for measuring apoptosis in ... for assessing reagent performance; washing, reaction and ...
... ApopTag Red In Situ Apoptosis Detection ... the indirect TUNEL method, utilizing an ... The kit provides indirect immunofluorescence staining ... using either fluorescence microscopy or flow ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
Biology Products: